Sustained RPM sluggishness
The company's relevant market (RPM) grew at 3-3.5% vs IPM 8%, and if this cyclicity persists, it could cap growth despite internal improvements.
JAGSNPHARM / Q3-FY26 / risks
Keep the risk register visible.
Jagsonpal Pharmaceuticals · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
medium
Elevated M&A valuations hindering capital deployment
Management noted that assets are highly priced, making disciplined M&A difficult, which could delay productive use of the ₹176 crore cash pile.
Field force productivity still below peers
Management acknowledged that MR productivity is below peer levels, and improvement is critical to achieving double-digit growth targets.